In fact, recent discoveries pointed out the immunological properties of therapeutic strategies against ALK, such as ALK peptide vaccination in NSCLC and chimeric antigen receptor (CAR)-T cell therapy against ALK in neuroblastoma [43,44]. The gene discussed is ALK; the disease is neuroblastoma.